Recent Press Releases

European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

In Phase 3 clinical trials, VIEKIRAX + EXVIERA cured 95-100 percent of genotype 1 chronic hepatitis C patients, with less than 2 percent of patients experiencing virologic failure[1],[2] -...

MICROVAX CANCER VACCINE FIRST IN HUMAN CLINICAL TRIAL IN SINGAPORE

Singapore, 12 August 2014 – MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine...

Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer

Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab

THOUSAND

Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion

Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for...

Vince & Associates Clinical Research Joins Cardiac Safety Research Consortium

Vince & Associates Clinical Research Joins Cardiac Safety Research Consortium

Vince & Associates Clinical Research

jcabana@vinceandassociates.com

Vince & Associates Clinical Research Joins Cardiac Safety Research Consortium

Overland Park, Kansas - Vince & Associates Clinical Research announced today its membership into the Cardiac Safety Research Consortium (CSRC). As a member of the CSRC, Vince & Associates...

Gilead Denied Patent for Hepatitis C drug sofosbuvir in India

The Indian Patent Controller today rejected one of Gilead's key patent applications which covered the drug sofosbuvir, used to treat hepatitis C (HCV). The oral drug, which first received regulatory...

Sanofi Enters Strategic Manufacturing Collaboration with Boehringer Ingelheim To Produce Biologics

Sanofi Enters Strategic Manufacturing Collaboration with Boehringer Ingelheim To Produce Biologics Paris, France - January 15, 2015 - Sanofi announced today it has entered into a strategic...

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals Ingelheim, Germany - 15 January 2015 - Boehringer Ingelheim and Sanofi...

Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples

LA JOLLA, Calif., Jan. 14, 2015 /PRNewswire/ -- Human Longevity, Inc.

Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies

BOTHELL, Wash. & NEW YORK--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial...

PEGASUS-TIMI 54 STUDY OF BRILINTA® MEETS PRIMARY ENDPOINT IN BOTH 60MG AND 90MG DOSES

Both BRILINTA 60mg and 90mg demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack 14 January 2015 AstraZeneca today...

Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote

Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote SOUTH SAN FRANCISCO, Calif., Jan 12, 2015...

Thermo Fisher Scientific Releases New CE-IVD Tumor Panel for Next Generation Sequencing

Thermo Fisher Scientific Releases New CE-IVD Tumor Panel for Next Generation Sequencing

Media:Thermo Fisher ScientificSuzanne Clancy, 760-602-4545

NHS increases budget for cancer drugs fund from £280 million in 2014/15 to an expected £340 million in 2015/16

NHS increases budget for cancer drugs fund from £280 million in 2014/15 to an expected £340 million in 2015/16 The NHS Cancer Drugs Fund (CDF) today (Monday) published the outcome of its...

Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome

MD Anderson's Moon Shots Program key to Collaboration

THOUSAND OAKS, Calif. and HOUSTON,

Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance

- Earnings and Business Update Scheduled for February 18th - DUBLIN, Jan. 12, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), in advance of the start of the 33rd Annual J.P. Morgan Healthcare...

Earnings and Business Update Scheduled for February 18th

DUBLIN, Jan. 12, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), in advance of the start of the 33rd Annual J.P. Morgan Healthcare Conference, today announced that based on a preliminary review of 2014...